An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies

BACKGROUND: The transmembrane receptor tyrosine kinase HER2 is overexpressed in approximately 15% of breast tumors and correlates with poor clinical prognosis. Several treatments that target HER2 are approved for treatment of HER2-positive metastatic breast cancer. The serum biomarkers most widely u...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrier, Alexandre, Boelle, Pierre-Yves, Chrétien, Yves, Gligorov, Joseph, Lotz, Jean-Pierre, Brault, Didier, Comperat, Eva, Lefèvre, Guillaume, Boissan, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946590/
https://www.ncbi.nlm.nih.gov/pubmed/31910438
http://dx.doi.org/10.1371/journal.pone.0227356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946590/
https://www.ncbi.nlm.nih.gov/pubmed/31910438
http://dx.doi.org/10.1371/journal.pone.0227356

Ejemplares similares